Endocrinology and Metabolism

Original Article

Mineral, Bone & Muscle
Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea: Yumie Rhee, Dong-Gune Chang, Jeonghoon Ha, Sooa Kim, Yusun Lee, Euna Jo, Jung-Min Koh; Endocrinol Metab. 2022;37(3):497-505. Published online June 3, 2022; DOI: https://doi.org/10.3803/EnM.2022.1427

15,267 View
403 Download
19 Web of Science
22 Crossref

Background
The efficacy and safety of denosumab have been established in a phase 3, randomized, placebo-controlled trial in Korean postmenopausal women with osteoporosis. This postmarketing surveillance study was aimed to investigate the safety and effectiveness of denosumab in Korean real-world clinical practice.
Methods
Patients with osteoporosis who had received denosumab per the Korean approved indications in the postmarketing setting between September 2014 and September 2019 were enrolled. The primary endpoint was the incidence of adverse events (AEs) and adverse drug reactions (ADRs). The secondary endpoint was the percent change from baseline in bone mineral density (BMD) of the lumbar spine, total hip, and femoral neck.
Results
Of the 3,221 patients enrolled, 3,185 were included in the safety analysis set; 2,973 (93.3%) were female, and the mean± standard deviation (SD) age was 68.9±9.9 years. The mean±SD study period was 350.0±71.4 days. AEs, fatal AEs, and ADRs occurred in 19.3%, 0.8%, and 1.6%, respectively. The most frequent AEs, occurring in >0.5% of patients, were dizziness (0.7%), arthralgia (0.7%), back pain (0.6%), and myalgia (0.6%). Hypocalcemia occurred in 0.3% of patients. There were no cases of osteonecrosis of the jaw and atypical femoral fracture. Mean±SD percent change from baseline in BMD of the lumbar spine, total hip, and femoral neck was 7.3%±23.6%, 3.6%±31.4%, and 3.2%±10.7%, respectively.
Conclusion
The safety and effectiveness of denosumab in Korean patients with osteoporosis in this study were comparable with those in the Korean randomized controlled trial, with no new safety findings.

Citations

Citations to this article as recorded by

Therapeutic strategy for exosome-based bone regeneration to osteoporosis: Challenges and potential solutions
Anoop Puthiyoth Dayanandan, Alvin Bacero Bello, Yoshie Arai, Sang Jin Lee, Soo-Hong Lee
Journal of Advanced Research.2026; 84: 361. CrossRef
The Survival of Dental Implants in Post‐Menopausal Women Receiving Denosumab: A Retrospective Cohort Study
Junghye Hwang, Youngjae Yoon, Garam Byun, Byung‐Joon Choi, Joo‐Young Ohe, Baek‐Soo Lee, Junho Jung
Clinical Implant Dentistry and Related Research.2026;[Epub] CrossRef
Effectiveness and safety of denosumab on osteoporosis treatment in kidney transplant recipients
Jin Kyung Kwon, Yaerim Kim, Jin Hyuk Paek, Kyubok Jin, Seungyeup Han, Woo Yeong Park
Kidney Research and Clinical Practice.2026; 45(5): 818. CrossRef
Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek
Endocrinology and Metabolism.2025; 40(1): 47. CrossRef
Does the Use of Denosumab in Combination with bDMARDs or tsDMARDs Increase the Risk of Infection in Patients with Osteoporosis and Inflammatory Rheumatic Diseases?
Salim Mısırcı, Ali Ekin, Burcu Yağız, Belkıs Nihan Coşkun, Mustafa Çağatay Büyükuysal, Ediz Dalkılıç, Yavuz Pehlivan
Journal of Clinical Medicine.2025; 14(17): 6090. CrossRef
Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?
Stanley B. Cohen, Kenneth G. Saag
The Journal of Rheumatology.2025; 52(9): 855. CrossRef
Comparison of the Efficacy of Denosumab in Patients at High or Very High Risk of Osteoporotic Fractures
Yeong-Gwon Jo, Sung Hyuk Yoon, Woo-Kie Min
Journal of Korean Society of Spine Surgery.2025; 32(3): 54. CrossRef
Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies
Ali Afshari, Jafar Karami, Mitra Abbasifard
Inflammopharmacology.2025; 33(12): 7217. CrossRef
Effects of Sequential Anti-Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study)
Jeonghoon Ha, Kyong Yeun Jung, Kyoung Jin Kim, Seong Hee Ahn, Hyo-Jeong Kim, Yoon-Sok Chung
Endocrinology and Metabolism.2025; 40(5): 748. CrossRef
DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM
Nguyen Van Tuan, Ho Pham Thuc Lan
Tạp chí Sức khỏe và Lão hóa.2025; 1(5): 4. CrossRef
Updated Advances on Drugs and Bone-Targeting Nanoparticles for Osteoporosis Therapy: Carrier Materials, Modification, Function Mechanism, and Applications—A Systematic Review
Yehao Lin, Yidong Xu, Siyue Zhou, Junyu Liu, Min Zhang, Baoxin Zhang, Haixia Chen
Pharmaceuticals.2025; 18(12): 1809. CrossRef
Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation
Young-Ho Cho, Seong-Eun Byun, Hwan-Hee Lee
Scientific Reports.2025;[Epub] CrossRef
Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection
Anna Spångeus, Johan Rydetun, Mischa Woisetschläger
Osteoporosis International.2024; 35(1): 173. CrossRef
Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
Huei-Kai Huang, Albert Tzu-Ming Chuang, Tzu-Chi Liao, Shih-Chieh Shao, Peter Pin-Sung Liu, Yu-Kang Tu, Edward Chia-Cheng Lai
JAMA Network Open.2024; 7(2): e2354734. CrossRef
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
Yue He, Rong Zhang, Huarui Shen, Yingqi Liu
Frontiers in Pharmacology.2024;[Epub] CrossRef
Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years
Jeongmin Lee, Youn-Ju Lee, Jeonghoon Ha
Journal of Bone Metabolism.2024; 31(3): 246. CrossRef
Adverse Effects of Denosumab in Kidney Transplant Recipients: A 20-Year Retrospective Single-Center Observation Study in Central Taiwan
Tsung-Yin Tsai, Zi-Hong You, Shang-Feng Tsai, Ming-Ju Wu, Tung-Min Yu, Ya-Wen Chuang, Yung-Chieh Lin, Ya-Lian Deng, Chiann-Yi Hsu, Cheng-Hsu Chen
Transplantation Proceedings.2023; 55(4): 837. CrossRef
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
Endocrinology and Metabolism.2023; 38(2): 260. CrossRef
Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
Chaiho Jeong, Jinyoung Kim, Jeongmin Lee, Yejee Lim, Dong-Jun Lim, Ki-Hyun Baek, Jeonghoon Ha
Journal of Clinical Medicine.2023; 12(21): 6904. CrossRef
Denosumab

Reactions Weekly.2022; 1919(1): 221. CrossRef
Denosumab, an effective osteoporosis treatment option for men
Sung Hye Kong
The Korean Journal of Internal Medicine.2022; 37(5): 947. CrossRef

First
Prev
Page of 1
Next
Last

Search